We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Vertex Pharmaceuticals Inc | NASDAQ:VRTX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.92 | 0.23% | 401.08 | 400.68 | 404.95 | 405.665 | 397.59 | 401.50 | 1,063,888 | 22:51:14 |
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jeffrey Leiden, M.D., Ph.D., Chairman, President & CEO of Vertex will present at the UBS Healthcare Conference in New York, NY on Tuesday, May 19th at 11:00 a.m. ET.
The audio portion of management’s remarks from the conference will be accessible live through Vertex’s website at www.vrtx.com in the “Investors” section under the “Events and Presentations” page. A replay of the conference webcast will be archived on the company’s website.
About Vertex
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to our clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases.
Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For five years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences. For additional information and the latest updates from the company, please visit www.vrtx.com.
(VRTX-WEB)
Vertex Pharmaceuticals IncorporatedInvestors:Michael Partridge, 617-341-6108orKelly Lewis, 617-961-7530
1 Year Vertex Pharmaceuticals Chart |
1 Month Vertex Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions